The Exchange had sought clarification from Valiant Laboratories Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
NSE asked Valiant Laboratories Limited to clarify certain points about its financial results for the quarter ended 31 March 2026, as required under Regulation 33 of the SEBI Listing Rules. The company has submitted its written response to the exchange, which is enclosed with this filing. The actual content of the clarification or response is not visible in the headline itself. The exchange typically raises such queries on matters like unusual movements, segment numbers, or audit observations.
This is a routine exchange query, but the underlying reason for the clarification could affect investor sentiment depending on what was asked. Shareholders should read the enclosed response to understand if any material concern was flagged.